Saturday, July 11, 2026

Drug profile · INN

gepotidacin mesylate

gepotidacin mesylate (BLUJEPA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — gepotidacin mesylate
US status
approved
Class
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

gepotidacin mesylate (BLUJEPA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN gepotidacin mesylate
Brand BLUJEPA
Route ORAL
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Gepotidacin Phase 3 · GSK Glaxo Smith · Urinary Tract Infections

Frequently asked questions

What is gepotidacin mesylate?

gepotidacin mesylate (BLUJEPA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for gepotidacin mesylate?

BLUJEPA is a marketed brand name for gepotidacin mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of gepotidacin mesylate?

gepotidacin mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.